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Views on Biotechnology 
GEORGEB.RATHMANN 
George B. Rathmann is President and Chief Executive Officer of Amgen Inc. 
Introduction 
Biotechnology is a most remarkable technology. I will 
present examples of the biotechnology revolution in widely 
diverse areas, including evidence that biotechnology is 
remaking the way the world discovers and develops pharma-
ceuticals and proof that the United States leads the world in 
this field. Then, I'll address the issues that have caused some 
to say that we should proceed slowly, cautiously, or possibly 
not at all. I'll comment on the questions of whether biotech· 
nology is safe, wise, and moral and look at both the national 
and international perspectives. 
This exciting story began in the 50s, when Watson and Crick 
said that the greatest impact of their elucidation of the double 
helical structure of DNA would be a rapidly growing under· 
standing of all life processes. They correctly assessed the 
power of DNA and the importance ofbeing able to understand 
its structure and manipulate DNA in the laboratory. How 
important is DNA to each of us? It turns out that these long 
molecules, which represent the blueprints of life are present 
in every living cell and the amount in each human being, if 
stretched end-to-end, would reach to the sun and back about 
150 times. So there is a lot of DNA. An A.mgen scientific 
advisory board member once stated that the elegance of DNA 
is that each cell contains sufficient information to be equival-
ent to about five encyclopedias. I accept that as a better 
definition of DNA. It surely is the most elegant matter in the 
universe. 
Manipulating DNA permits us to use the mechanisms of 
living cells to make products. It might seem fairly limiting to 
only make things that are produced by living cells. But the 
extraordinary diversity of life makes it possible to make such 
simple molecules as alcohols and esters, acids and amino 
acids and then, through metabolic pathways, to make compli-
cated enzymes, vitamins, proteins, and, of course, also to 
make DNA itself. So living cells have a great diversity, and the 
capabiliry to harness DNA has ushered in the biotechnology 
revolution. 
Where are the products of biotechnology produced? Not 
always, but very frequently in bacteria called E. coli. In the case 
of the product interferon, it is produced by the bacterium in 
such large quantities that the interferon is sequestered into 
little inclusion bodies, thereby helping partially purify the 
protein that we want to produce. The production of such a 
prodigious quantity of protein literally disables the bacteri urn 
to the point where it can no longer reproduce. As a result, we 
not only have to be able to insert the human interferon gene 
into the E. coli, we must also be able to turn the gene on at will. 
The bacteria must be allowed to multiply first. 
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This decade began with the announcement in]anuary 1 
that Charles Weissman was successfully producing the 
wonder drug interferon in a bacterium (1). Interferon is o~ 
today, after seven years, beginning to live up to the grea~ 
expectations of that time. However, the true significance of 
this announcement was that it stimulated the formation 
many new companies that have helped establish the United 
States' leadership position. And, of course, in addition, there 
was an explosion of optimism about biotechnology. 
Progress in Biotechnology to Date 
Bioprocessing 
One of the early promising potentials of biotech appeared 
to be in biomass conversion, to address the serious ener~­
problems faced by the United States in the early 1980s when 
fuel prices rose. The thought of supplying simple chemicals 
by this new technology was very attractive, but the changes in 
oil prices from earlier projections made it uneconomical to try 
to make ethanol and other fuels through biotech. Such ·work. 
heavily subsidized, is still being done, and certainly will be 
important some time in the next century as the availability of 
fossil fuels diminishes. 
The production of more complicated molecules via bio-
processing continues to offer exciting possibilities. An exam-
ple of such bioprocessing is the production of indigo dye ~­
bacterial cells. This capability was discovered accidentally 
when a scientist transferring a biochemical pathway from one 
bacteria into another noticed that his cells were turning blue. 
The two pathways had interacted to produce indigo, the dye 
used for blue jeans. (Indigo has been produced by synthetic 
organic chemicals for the past 100 years and was first isolated 
from plants more than 2,000 years ago.) 
The exciting thing about bioprocessing is that it opens u 
the prospect of room temperature production of chemicals. 
not the cheapest ones, not the simple alcohols and acids, b 
more complicated chemicals that can be produced at room 
temperature without toxic catalysts, without toxic fumes, and 
without side reactions because biochemical processes can be 
highly specific. There is great potential for the production of a 
number of other molecules including vitamin C, other vitam-
ins and enzymes. The first wave in the chemical field will be 
more complicated molecules than were originally emisi-
oned, but very important products with significant environ-
mental impact. 
Agriculture 
In the area of agriculture, a number of companies haYe 
shown that modified bacteria can improve the conversion of 
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nitrogen into the nitrates necessary for plant growth. When 
corn and other food crops can benefit from these advances, 
the reduction in the use of nitrate fertilizers that will be 
possible will have a profound environmental impact. In addi-
tion, plants have been genetically altered to resist insects or to 
have natural resistance to viruses and other pathogens. The 
impact of these developments is certainly going to be impress-
ive, but the impact on the environment may be even more 
beneficial. 
In summary, within the past six years genes have been 
introduced into plants to provide herbicide, insect, and path-
ogen resistance. The expression of the introduced genes can 
be controlled to produce the desired gene products. These 
genes are capable of being passed from generation to 
generation. 
Animal Production and Health 
In the areas of animal production and health, milk produc-
tion has been increased safely in large numbers of animals, 
and improved meat quality is now possible. Recombinant 
vaccines have also been introduced for animals, and much 
progress has been made in general disease control. 
For example, the administration of the hormone bovine 
somatotropin yields a 15-20% improvement in milk produc-
tion for only a slight increase in feed. That is, the feed effi-
ciency conversion to milk has been improved. Detection 
systems for determining how much administered somato-
tropin is in the milk show that the amount is essentially the 
same as is found in milk naturally; bovine somatotropin is a 
natural animal hormone that already exists in the cow. 
In the case of pigs, the administration of porcine somato-
tropin produces a much leaner meat, a much healthier food, 
with again more efficient conversion from feed to meat. It is 
estimated that 50 million pigs will receive this product when it 
is approved. 
This work has led people to speculate that soon we will 
have animals of weird shapes, designed to serve man and that 
we will forget about our responsibility to living things. How-
ever, I don't foresee a lot of chimeric animals. But, we should 
see the possibility of single cell proteins as a major source of 
protein for the world. Some big companies have bet on this 
already. Protein is produced with almost economic efficiency 
today in large containers that don't have any animals and these 
proteins don't even require sunlight. It's disease free, high 
quality protein. You can adjust the amino acid ratios to make 
sure the protein is perfect. However, it is not a food to which 
we are accustomed and it probably will take a long time to get 
accustomed to it. This type of food will happen before' we 
have strange animals running around in the world; it is a safe 
and efficient way to meet humankind's nutritional needs. 
Diagnostics 
There has been great progress in diagnostics in the last six 
years. While monoclonal antibodies are not strictly speaking a 
product of recombinant DNA, they are certainly a product of 
advanced biotechnology. These very specific immunosystems 
provide specificity down to submolecular levels. Hybridiza-
tion probes, which essentially use the binding action of DNA 
(exactly the same binding that holds the double helix 
together), have sensitivities down to 10-Js M. The long-range 
potential here is much earlier detection of disease so we can 
treat it when it is still treatable. The detection of diseases in the 
pre-natal stage or genetic screening may also be possible. 
Lastly, of course, the discovery of oncogenes and their link to 
cancer has given us new insights into that incredibly complex 
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process and new cancer diagnostics are underway. Diagnos-
tics are moving relatively rapidly now. 
Pharmaceuticals 
The major progress that has been most exciting to the world 
in the past several years has been in the pharmaceutical arena. 
Eight products are now marketed. All the targeted human 
proteins originally projected have been cloned, expressed, 
and produced at some level, including some very complex 
human proteins such as Factor VIII used to treat hemophilia. 
There are high expression (production levels) available so 
these materials can be produced practically, alleviating early 
concerns about whether enough product could be made. It 
turns out that for some of these materials one or two pounds 
will treat the world for a whole year. 
Vaccines of a brand new type have been developed. They 
do not contain any of the pathogenic organism's DNA and 
cannot replicate. A problem of some conventional vaccines is 
sudden reversion and infection by the vaccine itself-no 
longer a risk with the new vaccines based on recombinant 
DNA. Here a little bit of the coat protein becomes the stimulus 
for the body's immune system and no pathogen is introduced 
at all. Magic bullets have been produced in which targeted 
antibodies carry toxins and destroy pathogenic cells. Major 
progress has been made in the past six years. 
One of the exciting pharmaceuticals available, erythropoie-
tin, is used to stimulate red blood cell production to combat 
certain forms of anemia. It takes about 20 micrograms or less 
per day of erythropoietin to restore normal red cell levels for 
many people, as compared to a maximum daily dose for 
things like Motrin or Tagamet of approximately two grams. 
When compared on a weight basis, erythropoietin is 100,000 
times more potent, and on a molecular basis, it is 10 million 
times more potent. Therefore, we can use 1/10 millionth as 
many molecules to produce the therapeutic result. In addi-
tion, erythropoietin is a normal human protein which is 
exactly like, or very, very close to what is in the body already, 
and which has the metabolic pathways of products that 
already exist in our bloodstream. We are talking about a 
specificity so high that the probability of side effects is abso-
lutely minimal. It is on this basis that it is clear that recombi-
nant DNA affords a new way to produce pharmaceuticals. 
A clinical study on erythropoietin, which has gone on now 
for a year and a half, indicates that there is a dose dependent 
response. Patients that were transfusion dependent can be 
taken off transfusions. There is no organ dysfunction, no 
antibody formation. The kind of data shown is some of the 
finest quantitative human data that has ever been seen with 
patient after patient showing responses in hematocrit level 
that increase very consistently depending upon the level of 
the drug administered. It is almost an idealized curve. Examin-
ing the case of a single patient is quite revealing. This patient 
had received 14 units of packed red cells in the previous 20 
weeks. He was then placed on erythropoietin and given no 
more transfusions. The red blood cell level (the hematocrit of 
the patient) went up to normal. With transfusions this patient 
could not achieve above a 25 hematocrit, which is about 60% 
of normal. So we see a dramatic result from, again, micros-
copic quantities of these natural human proteins (2). 
Two other products of biotechnology are tissue plasmino-
gen activator or t- PA and granulocyte colony stimulating factor 
( G-CSF). Administration oft-PA can dissolve clots in coronary 
arteries interrupting a heart attack 
Treatment with G-CSF results in a large increase in white 
cells, largely neutrophils. This is exactly what the patient 
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needs in many cases. When cancer treatments destroy the 
body's ability to make white cells, the ones that disappear first , 
the neutrophils, are the cells that disarm the body's immune 
system. By restoring the body's neutrophils, we can bring 
patients back to normal. After a round of cancer chemother-
apy, if the patient has been treated with G-CSF, studies on a 
small but meaningful number of patients indicate that the 
neutrophil level never drops below safe levels. The product 
looks very promising and it has a number of other applications 
in cancer therapy as well. G-CSF is perhaps one year behind 
erythropoietin in the extent of clinical studies completed anq, 
of course, those will be necessary for final approval. 
The exciting aspect of some of these highly directed thera-
pies is the contrast they show to some of the earlier recombi-
nant proteins that had broad responses but a wide spectrum of 
side effects. G-CSF and erythropoietin do not have the broad 
spectrum of response-each does only one thing, but it does 
it very well indeed. It does it without side effects. 
Protein Engineering 
An exciting new dimension ofbiotechnology that is still large-
ly in the future is protein engineering. The concept here is that 
analogs to natural proteins can be made by altering the gene 
for that protein. We can take out a few segments of the gene 
and replace them with other segments. This is all straightfor-
ward molecular biology today. The net effect is that we can 
introduce new amino acids at will. The protein generated 
might look similar, or it might be that when the new unit is 
introduced the whole configuration assumes a very different 
shape. Most often if you introduce a new amino acid in a 
protein, its characteristics will be destroyed, but if you are very 
selective and do it in the right way, you can occasionally 
improve the product. 
Scientists at Amgen took a somewhat different approach to 
protein engineering of alpha interferon. Recognizing that 
there are 14 kinds of alpha interferon and that a lot of homol-
ogy or uniformity exists among the 14 types (see Figure 1), 
they concluded that nature was trying to make the concensus 
molecule. We averaged all of the 14 structures and produced 
that gene and its protein product. (Of course, with genetic 
engineering today, that is a very quick job. One can make the 
gene and produce the protein in a few weeks.) Our scientists 
found their product was, in fact, an active interferon, possibly 
five times more active than any of the 14 common ones. This 
protein is changed by 14 amino acids from all the others-a 
lot of amino acid changes-and yet has improved protein 
activity, a most unlikely event. It is obviously a very interesting 
product. It is now in advanced testing against viral diseases 
and it looks as if it will be a useful antiviral agent. 
Results vs. Forecasts 
Two years ago at an Industrial Research Institute Confer-
ence here in Minnesota, Paine Webber presented projections 
for market dates for eleven biologicals (Figure 2). I endorsed 
those figures. How well have our forecasts done? At that time 
projected marketing for alpha interferon was 1985-87; it went 
on the market in 1986 to treat one of the deadliest of cancers, 
hairy cell leukemia. From a market standpoint, a small market. 
From an importance standpoint, at least for the affected 
patients, it is life and death. Beta interferon has not been 
introduced yet, although there are some indications for antivi-
ral activity. Also, there is hope that it has anti-cancer proper-
ties. It has been approved outside the United States but not 
here yet. Probably it will be marketed within those dates. For 
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the product erythropoietin, 1990-1992 actually looks conser-
vative. It could well be on the market in the very first part of 
that period, but then Food and Drug Administration (FDA) 
approval is not easy. The date projected for gamma interferon 
(1987-1989) may be a little early. Marketing could be later 
than 1989 because of the spectrum of responses the drug has 
had-it is very hard to identify where it fits in. In many cases, 
the side effects overwhelm the benefits. It is not clear that it 
will hit that date. Hepatitis B vaccine went on the market in 
1986, earlier than projected. This vaccine is a very important 
contribution since 250 million people in the world are 
infected with that disease. They will not be helped by the 
vaccine, but future infections could be prevented. 
Human growth hormone went on the market in 1985, and a 
second version of that hormone is going on the market right 
now; therefore, two products will be marketed by 1987. For 
interleukin-2, there were some very exciting early data (3) , 
some more disappointing data ( 4) , and then a reactivation of 
interest in this drug in recent publications in The New Eng-
land journal of Medicine(5, 6). It certainly looks as if it will be 
marketed by 1989, but not by 1987. 
Monoclonal antibodies can target toxins, serving as magic 
bullets against cancer and magic bullets against infections. It is 
difficult to project market dates right now, but development 
appears to be on schedule. 
Tissue plasminogen activator is definitely scheduled for 
this year. It could be the largest biotechnology product for 
many years to come. 
Tumor necrosis factor is a complex biological response 
modifier with many effects other than just simply destroying 
tumors, which it does do. Balancing the side effects in human 
testing has not been achieved yet. But 1990-1991 is still a 
probable marketing date. 
I'd like to assert and support the idea that the United States 
is leading the world in biotechnology. My view is largely the 
result of having traveled around the world and visited with all 
the other companies and noted the number of companies 
around the world that want Amgen to work with them. We 
have many relationships. There are more than 150 relation-
ships between major Japanese companies and small U.S. bio-
technology companies. I think that speaks clearly for where 
the Japanese think the Americans are. There is no doubt in our 
mind that the United States leads in this race. There is also no 
doubt that some of the commitments of other countries are 
very strong and that gap could close. Certainly it is a good time 
to address the balance of trade issues rather than wait until 
we're beaten and then try to restore balance by tariffs and 
other things. That is important to keep in mind. Other factors 
are much more important. The welfare of the people in this 
country. The benefits of these products here and around the 
world is certainly more important than just deciding we have a 
commitment to lead. 
With two versions of alpha interferon, as well as insulin, 
human growth hormone, and the hepatitis B vaccine on the 
market and 30 more products in the development pipeline, 
the United States is well ahead in product development. 
Indeed each of these productss was introduced into clinical 
studies by U.S. firms. 
Concerns about Biotechnology 
Now let us consider some of the issues that have been 
raised about pursuing biotechnolgy, addressing the federal 
issues first. Arthur D. Little, a leading management and tech-
nology consulting firm, has suggested that there are some 
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COMPARISON OF IFN - a STRUCTURES 
Subtype 10 20 
IFN - A C D L P Q T H S L G S R R T L M L L A Q M R K S 
IFN - D C D L P E T H S L 0 N R R T L M L L A Q M S R S 
IFN - 5 C 0 L P Q T H S L S N R R T L M I M A Q M G R S 
IFN - 6 C 0 L P Q T H S L G H R R T M M L L A Q M R R S 
IFN - C C 0 L P Q T H S L G N R R A L I L L G Q M G R S 
IFN - c1 C 0 L P Q T H S L R N R R A L I L L A Q M G R S 
IFN - 4b C 0 L P Q T H S L G N R R A L I L L A Q M G R S 
IFN - 7 4 C 0 L P Q T H S L G N R R A L I L L A Q M G R S 
IFN - I C 0 L P Q T H S L G N R R A L I L L A Q M G R S 
IFN - L C 0 L P Q T H T L R N R R A L I L L G Q M G R S 
IFN - J C 0 L P Q T H S L R N R R A L I L L A Q M G R S 
IFN - H C N L S a T H S L N N R R T L M L M A a M R R S 
IFN - F C 0 L P Q T H S L G N R R A L I L L A Q M G R S 
IFN - 8 C 0 L P Q T H S L G N R R A L I L L A a M R R S 
IFN - aCon1 C D L P Q T H S L G S R R A L I L L A Q M R R S 
~-------------~ 
Figure 1. Comparison of the first 25 amino acids of the 14 naturally occurring forms of interferon. The bottom row is the consensus 
sequence generated by AMGen. 
serious issues with respect to university and industry relation-
ships, questioning whether we have perturbed the university's 
role (7). Actually, this concern was highlighted in 1981 by 
Robert Sinsheimer, in an address at the University of Califor-
nia, Santa Cruz, who said, ''This spectacle of faculty seeking to 
exploit their research as private entrepreneurs is a scene 
fraught with conflicts of interest, destructive of collegiality, 
and erosive of the credibility of the university as a source of 
disinterested expertise" (8). Manywere extremely concerned 
about this and we should be concerned and alert at all times 
about the change of the role of the university, which is so vital 
to our society. Our experience has been that although many 
leading academic people have affiliated themselves with bio-
tech companies, we have never tried to control any of their 
publications. We don't review their publications and we don't 
fund programs dedicated to our interests. We have issued 
some grants, not many however, because of the fear that it 
might look as though we are trying to buy their research for us. 
I haven't noted any diminution in their dedication to their 
students or the principles of the promotion of science in this 
country. 
Commercialization of biotechnology, of course, is the flip 
side of this. If we are going to promote it, how can we do it 
well? How can we do it safely? There is also the issue of risks. 
Are there risks? There must always be some. Let's make sure 
we're not glossing over them. Let's avoid secrecy at all costs. 
Let's respect the intellect of the American public and its ability 
to understand. Let's not decide what people don't know won't 
hurt them. Let's make sure they do understand these risks. 
A number of recommendations for action concerning bio-
technology policy have been suggested both by A.D. Little and 
others (7). U.S. leadership developed in the first place when 
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federal support of research was coupled with the.free enter-
prise of commercialization of biotechnology in small com-
panies. Support of research should never be eliminated. The 
National Science Foundation (NSF) is going to double its 
budget in the next five years, but some biological research has 
not been growing as rapidly, or even been supported ade-
quately, in the past couple of years. Supporting development 
sounds great. Let's do that too, but I am concerned that federal 
support of development may reduce the amount of research 
supported. Moreover, while research and development tax 
breaks sound great, a small company like ours didn't make 
money for four years. It really isn't a lot of help not to pay taxes 
when company losses mean no taxes are owed. While it is 
great for some companies, it doesn't really stimulate the 
growth of small companies, which I think is a very important 
goal. 
Expedite patent action. There is a lot that could be said 
about the patent system. A lot of people don't understand it 
who should understand it. First, everybody associates the 
patent system with secrecy, while in fact, it has the opposite 
effect. You can keep a secret or you can patent it. When you 
patent it, you are going to file an application that represents 
the best embodiment of what you have. Our patents teach you 
exactly how to make our products. Within 18 months of the 
date we file those patent applications, they are published in 
full overseas and around the world. They are picked up by 
every country and by every other company. The unfortunate 
thing is that we are providing the information in exchange for 
patents, which are delayed for years and years because of the 
backlog in the Patent Office. I think the United States is 
disadvantaged in this regard. Creative companies are disad-
vantaged because they are providing the information and it is 
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PROJECTED MARKET DATES FOR 11 BIOLOGICALS 
Product Market Date Company 
Alpha Interferon 1985-1987 Blogen/Scherlng-Piough 
Genentech/Hoffmann-La Roche 
Amgen (Concensus alpha) 
Beta Interferon 1987-1989 Cetus/Shell Oil 
Blogen/Scherlng-Piough 
Chiron/Lucky Ltd . 
Erythropoietin 1990-92 • Amgen/Kirln 
Genetics Institute 
Gamma Interferon 1987-1989 Blogen 
Genentech/Boehringer /Daiichi 
Amgen 
Source: Paine Webber Chlron/Lucky Ltd. 
PROJECTED MARKET DATES FOR 11 BIOLOGICALS 
Product 
Hepatitis B Vaccine 
Market Date 
1987-1988 




Source: Paine Webber 
1987-1989 
1989-1991 
Figure 2. Projected market dates for 11 biologicals. 
Company 
Merck/Chlron 
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Tumor Necrosis Factor 1990-1991 
Source: Paine Webber 
Figure 2. Projected market dates for 11 biologicals. 
too long before the corresponding patent rights are awarded. 
Many people worry about whether it is right to patent things 
that are used to treat human beings. The motivation to create 
these products is that you are going to be able to market them 
under circumstances where not everybody is equal. It wasn't 
equal when you discovered them; why should you be equal in 
the marketplace. That is the basis of the patent system, which 
has stood the test of time for a couple of hundred years and is a 
fine system for encouraging creation and innovations. How-
ever, problems occur when it takes too long to get the protec-
tion that the disclosures justify. -
People are interested also in expediting the regulatory 
process. There are always some fears when you say that-fears 
that we will have all sorts of disasters. However, when the 
regulatory process is so comprehensive that when you submit 
your documents to the FDA it may take a year to read them, 
you know there is something wrong with the process. The 
patients who are waiting for that drug could never compre-
hend taking two years to read the information that is going to 
make possible what they already know they want. 
Figure 3 summarizes the roles of various federal agencies in 
biotech development and regulations. The regulatory process 
and whether the government is adequately involved is illus-
trated here in more than enough detail, indicating just how 
many parts of the government are involved in supporting or 
investigating, regulating, controlling, or agitating about 
biotechnology. 
Probably the most controversial column on the chart indi-
cates the Department of Defense's (DoD) interaction with 













Blogen/ Sun tory /BASF 
biotech companies. Most of us have have a clear policy from 
the beginning. We have no secrets. We registered ourselves as 
a genetic engineering company in a community in California 
and we said if that is a concern to people, let's explain it to 
them. Let's not hide behind a different name. We've had no 
secrets. The DoD talked to us on one occasion. The ground 
rules they laid out was that we do not discuss biochemical or 
biological warfare, offensive or defensive. That was not going 
to come up. We had the discussion. We talked about things 
like erythropoietin and other materials. That is the only dis-
cussion our company has ever had. Some other companies, I 
am sure, have also had discussions. The government claims 
that it is not conducting offensive weapons research. We 
accept that. We certainly haven't. They are not doing any 
testing with us and I don't know of anybody with whom they 
are doing any. I think it has been of concern because secrecy is 
a deadly thing. When you don't hear about it, you don't know 
whether you're hearing everything or if something is being 
withheld. It is an issue. 
However, the issue I was trying to highlight here is the 
incredible involvement of the government already. Efforts to 
try to simplify this usually scare us into thinking that we're 
probably going to end up with something more complicated. 
Largely, the system is working. I think it is well controlled. I 
think we're over-controlled to some degree and I think it's too 
slow, but I don't think we're badly in need of some overlay of 
additional and additional layers. 
Hidden behind the question of how should the United 
States maintain its leadership in biotech, is an additional 
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FEDERAL AGENCY ACTIVITIES IN BIOTECHNOLOGY 
~ FDA USDA DOD/ NIH DOC EPA DOS OSTP NBS pSHA CDC NASA DOE DOl DOT NSF CRS ONR 6 
Commercialization • • • • • • • • 
Risk, Env. H&S • • • • 
Regulation • • • 
Long Term • • 
International • • • • • • • 
Coordination • • • • • • • • 
Innovation • • • • • 
Liability • 
Basic R&D • • • • • • • • • • 
Ethical • 
Manpower & • • • Training 
Figure 3. Activities of various federal agencies in the development and regulation of biotechnology (7). 
question, should the United States maintain its leadership 
position in biotechnology? A survey by Monsanto (Figure 4) 
indicates there are some concerns out there (9) . It is very 
important that we monitor these concerns, understand them, 
and try to have communication. Those surveyed were science 
policy leaders, environmental leaders, and religious leaders. 
Their most serious concern was the risk of creating undesira-
ble organisms. 
The surveyors also asked if the respondents believed that 
the benefits of biotechnology outweigh the risks. In fact, the 
science policy leaders feel so, the environmental leaders feel 
so with a little more ambivalence, and the religious leaders 
have major concerns. On the negative side, 27% of our reli-
gious leaders feel the risks outweigh the benefits. These are 
very important issues that should be addressed. Certainly if 
you feel the risks do outweigh the benefits, you shouldn't be 
trying to proceed and to maintain a leadership position in this 
field. We have some educating to do. 
There are also others with great concerns. Eugene P. Odum 
says that enthusiasm for biotech should not lead us to treat all 
organisms merely as commodities for short-term gain (10). 
The long·term risk that he fears is undoubtedly ecological. 
What he seems to underestimate is the fact that many biotech 
products will reduce environmental stress and be used to 
detect and clean up some ofthe toxins we are already trying to 
eliminate. 
Anthony Robbins, staff member on the Committee on 
Energy and Commerce, U.S. House of Representatives, says 
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everything is going to go toward drain cleaners and cosmetics 
( 11). My response to that is a list of vaccines that are in 
development for schistosomiasis, malaria, and for AIDS. There 
are more than a billion patients suffering from these diseases. 
Our hepatitis B vaccine has been tested in China where 1.8 
million babies a year, two a minute, are being infected by 
hepatitis directly from their mothers. The vaccine works. It 
prevents that process. Biotechnology has made great progress 
and it is clear that Robbins is underestimating the application 
of this technology to do good. 
Jeremy Rifkin, founder of the Foundation on Economic 
Trends and critic of genetic engineering, said, "Doesn't it 
make sense that we forestall biotechnology experiments until 
we've had a deep thorough national/international debate?" 
(12). He seems to think that will take a finite amount of time. 
We're concerned that the debate might well go on and 
although it might be a very important activity, it must go on in 
parallel with development if we wish to address the concerns 
of people who see biotechnology as having the best solution 
for their problems. Disease, nutrition, congenital defects, 
environment, aging, energy-they are all there to be dealt 
with and I don't think we can wait for the resolution of the 
total national/international debate. 
Conclusion 
In summary, biotechnology is solving problems with 
health , agriculture, and specialty chemicals. The United States 
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Figure 4. National survey of leaders in the fields of science policy, environmental issues, and religion on risks related to biotechnology. The 
survey was conducted by the Public Opinion Laboratory at Northern Illinois University and was sponsored by Monsanto (9). 
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leads in this development and really it is up to us to make sure 
that we get a broad enough understanding to maintain the 
support for this technology, to move it ahead with res-
ponsibility. 
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Knowledge is power. Never has that been truer than in 
today's information age, with the exponential increase in 
human knowledge, with our ever more powerful computing 
devices, and with our extraordinary means of communication. 
"Give me a place to stand and I will move the earth," said 
Archimedes. Today we know that the place to stand is at the 
console of a supercomputer. 
The other side ofthe coin, and there are always two sides, is 
to be found in Ecclesiastes; "He that increaseth knowledge, 
increaseth sorrow." The author of Ecclesiastes was not simply 
being morose or jaundiced. He knew that with increased 
knowledge inevitably comes increased responsibility, for 
good or for evil; together with the increased burden of deci-
sion; the wider potential for error; and the need for new 
ethical guidelines to define the boundaries of action in the 
new domain, wrested from the realm of innocence and ignor-
ance. 
Today we are at the verge of a most extraordinary advance in 
human knowledge, in the domain of the life sciences. We are 
about to achieve no less than a complete knowledge and 
understanding of the nature of life and the plan of evolution-
and thereby of ourselves-as a part of life, a product of evolu-
tion. 
16 
The science of biology, in its continuing analysis of the 
processes oflife, has penetrated to life's innermost secret-to 
the genes, to DNA, to the master programs that define the 
nature of each living cell and each living organism. 
The genetic programs are carried on the chromosomes in 
the structure of very long DNA molecules. The DNA molecules 
are the well-known double helixes composed of a ladder of 
nucleotide pairs. There are four kinds of pairs and their 
sequence conveys the hereditary information. A gene is a tract 
of several hundred or several thousand such pairs and is 
located in a particular region on a particular chromosome. 
We have already determined the complete genetic struc-
ture, the DNA sequence, of a few very simple organisms (up to 
170,000 nucleotide pairs) , and we now have the capacity and 
are setting out to determine the complete genetic structure of 
higher organisms and specifically, of man. A project is now 
being launched to sequence the entire human genome, some 
3 billion nucleotide pairs of DNA. It can surely be done. It is 
only a matter of time and efficient approach (1). 
This knowledge would permit a complete enumeration of 
the genetic ingredients of man. We estimate there are 100-
300,000 genes in Homo sapiens. These will now be defined 
and enumerated. 
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